HC Wainwright Boosts MetaVia (NASDAQ:MTVA) Price Target to $40.00

MetaVia (NASDAQ:MTVA) had its price target boosted by equities researchers at HC Wainwright from $12.00 to $40.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 387.21% from the stock’s current price.

Several other equities analysts have also issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of MetaVia in a report on Monday, December 22nd. Wall Street Zen upgraded MetaVia to a “sell” rating in a report on Saturday. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $36.50.

MetaVia Stock Performance

MTVA traded down $0.52 during midday trading on Tuesday, reaching $8.21. 27,013 shares of the company were exchanged, compared to its average volume of 28,380. The stock has a market capitalization of $18.06 million, a P/E ratio of -0.98 and a beta of 0.27. MetaVia has a one year low of $6.05 and a one year high of $28.49. The stock’s 50-day simple moving average is $8.90 and its 200 day simple moving average is $8.73.

MetaVia (NASDAQ:MTVA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($1.54) EPS for the quarter, beating analysts’ consensus estimates of ($2.86) by $1.32. On average, research analysts anticipate that MetaVia will post -3.9 earnings per share for the current year.

Hedge Funds Weigh In On MetaVia

A hedge fund recently raised its stake in MetaVia stock. SG Americas Securities LLC grew its holdings in MetaVia Inc. (NASDAQ:MTVA) by 44.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 60,386 shares of the company’s stock after purchasing an additional 18,506 shares during the period. SG Americas Securities LLC owned about 0.25% of MetaVia worth $57,000 at the end of the most recent quarter. 1.37% of the stock is owned by hedge funds and other institutional investors.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.